N/A N=101 Post- Approval Study on Patients Who Received a HeartWare HVAD® During IDE Trials
Heart Failure
Primary: Overall Survival on Device — 52.9 Percent Probability of Survival
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=194 Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation
Heart Failure, Congestive · Ventricular Dysfunction · Cardiomyopathies
Primary: Survival — 112; 6; 18; 19 participants
N/A N=75 Heart EXPAND Continued Access Protocol
Heart Transplant
Primary: Patient Survival at Day 30 Post-transplantation and Absence of Severe PGD (Left or Right Ventricle) in the First 24 Hours Post-transplantation — 72 Participants
N/A N=639 Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure
Chronic Heart Failure
Primary: The Primary Endpoint is Success at 180 Days Which is Defined as Alive on the Originally Implanted HeartWare® LVAD or Transplanted or Explanted for Recovery. Patient Must…
N/A N=75 International EXPAND Heart Pivotal Trial
Heart Transplant
Primary: Patient Survival at Day-30 Post Transplant and Absence of Severe Primary Heart Graft Dysfunction in the First 24 Hours Post-transplantation — 66 Participants — p=<0.0001
N/A N=72 Don't Throw Your Heart Away: Clinician Study 3
Cardiac Transplant Disorder
Primary: Hospital Choice — 4; 21; 34; 13 Participants
N/A N=90 Donor After Circulatory Death Heart CAP Trial
Heart Transplant
Primary: Patient Survival — 75 Participants
Phase 3 N=22 Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients
Orthotopic Heart Transplant
Primary: Coronary Flow Reserve (CFR) — 1.77 ratio: peak to baseline CFV
Phase 4 N=25 HCV Positive Heart Donors
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
Phase 1 N=14 Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology
Hypoplastic Left Heart Syndrome · Single Ventricle · Heart Failure
Primary: Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells — 0; 0 participants
Phase 3 N=102 Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Heart Transplant Recipients
Primary: Peak Oxygen Consumption — 23.9; 22.0 ml/kg/min
N/A N=200 Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy
Heart Failure, Congestive · Ventricular Dysfunction · Cardiomyopathies
Primary: Composite Endpoint — 46; 11 percentage of participants — p=0.00000025
Phase 2 N=20 Hyperbaric Oxygen Therapy for Lung Transplantation
Disorder Related to Lung Transplantation · Central Airway Stenosis · Airway Exudative Plaques
Primary: Subjects Needing Airway Stent Placement as Determined by Transbronchial Lung Biopsy. — 4; 4 Participants — p=1
Phase 4 N=14 Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement
Heart Failure
Primary: Pulmonary Hypertension — 31.4; 29.1; 25.9; 25.4 mmHg
N/A N=189 Physical Therapy and Occupational Therapy After Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve Implantation
Primary: Post Procedure Hospital Length of Stay — 4.8; 3.5 days
Phase 4 N=150 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients
Immunosuppression
Primary: Mean International Society for Heart and Lung Transplantation Biopsy Score Over the First 6 Months Post-transplantation — 0.7; 0.65 units on a scale
Phase 4 N=115 SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
Renal Function and Chronic Allograft Vasculopathy
Primary: Measured Glomerular Filtration Rate (mGFR), 12 Months After Heart Transplantation — 79.8; 61.5 mGFR ml/min
N/A N=13 A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
Portopulmonary Hypertension · Pulmonary Arterial Hypertension · Pulmonary Hypertension
Primary: Number of Subjects Who Achieved Hemodynamic Parameters Appropriate for Orthotopic Liver Transplantation Candidacy at Week 24. — 1; 12 participants
N/A N=6 Clinical Evaluation of HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure in Japan
Heart Failure
Primary: Number of Participants Alive on the Implanted HW005 Ventricular Assist System or Transplanted or Explanted for Recovery at 180 Days — 6 Participants
N/A N=88 Lung Transplant G0 (LTGO): Improving Self-Management of Exercise After Lung Transplantation
Exercise · Lung Transplantation
Primary: Physical Function- Walking: Change in Average Steps Per Day at Month 3 — 460; 352 average steps per day — p=0.8793
N/A N=180 Donors After Circulatory Death Heart Trial
Heart Transplant
Primary: Survival — 76; 75 Participants — p=<0.0001
Phase 2 N=18 Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation
Cardiac Allograft Vasculopathy
Primary: Insulin Levels Area Under Curve(AUC) — -47.7; 10.7 h*pmol/L
N/A N=105 Don't Throw Your Heart Away: Medical Student Study 2
Cardiac Transplant Disorder
Primary: Hospital Choice — 33; 47; 23; 2 Participants
N/A N=446 The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE Trial
Chronic Heart Failure
Primary: Stroke-Free Survival Probability for 2 Years Post Implant — 55.4; 59.1 Probabillity — p=0.0110
N/A N=60 Health Coaching to Improve Self-Management in Thoracic Transplant Candidates
Self-management · Lung Transplant · Heart Transplant
Primary: Score on Follow-up Self-Management Ability Scale (SMAS-30) — 75.06; 71.47 score on a scale
N/A N=321 CardioMEMS HF System OUS Post Market Study
Heart Failure · Left-Sided Heart Failure · Congestive Heart Failure
Primary: Freedom From Device/System Related Complications — 304 Participants
N/A N=144 HW006 LATERAL Thoracotomy
Left Sided Heart Failure
Primary: Subject is Alive on Original Device, Transplanted, or Explanted for Recovery at 6 Months — 128 Participants — p=0.0003
N/A N=96 Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year — 3.39; 3.65 mm3/mm
N/A N=445 PCORI-1310-06998 Trial of a Decision Support Intervention for Patients and Caregivers Offered Destination Therapy Heart Assist Device
Heart Failure · Heart-assist Devices
Primary: Reach of Intervention — 107; 64 Participants
Phase 4 N=181 Everolimus in de Novo Heart Transplant Recipients
Cardiac Transplantation
Primary: Participants With at Least One Occurrence of Safety Composite Endpoint After 6 Months by Treatment Group — 40; 30 participants — p=0.1043